Penumbra to be Acquired by Boston Scientific for $14.5 Billion in Cash and Stock
summarizeSummary
Penumbra has entered into a definitive merger agreement to be acquired by Boston Scientific, a major development that fundamentally alters the investment thesis for Penumbra shareholders. The acquisition price of $374 per share represents a significant premium over Penumbra's current stock price of $351.00 and its 52-week high of $325.025, indicating strong value for shareholders. The consideration structure, offering a mix of cash and Boston Scientific stock, provides flexibility while ensuring a substantial immediate return. This transaction is a major strategic move for both companies, with Penumbra's portfolio expanding Boston Scientific's presence in fast-growing vascular segments. The deal is subject to customary closing conditions, including shareholder and regulatory approvals, with an expected completion in 2026.
check_boxKey Events
-
Definitive Merger Agreement
Penumbra, Inc. has entered into an Agreement and Plan of Merger to be acquired by Boston Scientific Corporation.
-
Acquisition Price and Premium
The transaction values Penumbra at $374 per share, representing a significant premium to the current stock price of $351.00 and the 52-week high of $325.025.
-
Consideration Structure
Shareholders can elect to receive $374 in cash or 3.8721 shares of Boston Scientific common stock, subject to proration, resulting in approximately 73% cash and 27% stock.
-
Enterprise Value
The total enterprise value of the acquisition is approximately $14.5 billion.
auto_awesomeAnalysis
Penumbra has entered into a definitive merger agreement to be acquired by Boston Scientific, a major development that fundamentally alters the investment thesis for Penumbra shareholders. The acquisition price of $374 per share represents a significant premium over Penumbra's current stock price of $351.00 and its 52-week high of $325.025, indicating strong value for shareholders. The consideration structure, offering a mix of cash and Boston Scientific stock, provides flexibility while ensuring a substantial immediate return. This transaction is a major strategic move for both companies, with Penumbra's portfolio expanding Boston Scientific's presence in fast-growing vascular segments. The deal is subject to customary closing conditions, including shareholder and regulatory approvals, with an expected completion in 2026.
この提出時点で、PENは$351.00で取引されており、市場はNYSE、セクターはIndustrial Applications And Services、時価総額は約$122.7億でした。 52週の取引レンジは$221.26から$325.03でした。 この提出書類はポジティブの市場センチメント、重要度スコア10/10と評価されました。